Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome.

Abstract

OBJECTIVE Vascular endothelial growth factor (VEGF) plays an essential role in the pathophysiology of polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome. Anti-VEGF antibody (bevacizumab) appears to be an attractive therapeutic option. The aim of this study is to investigate the effects of bevacizumab for patients with… (More)
DOI: 10.1136/jnnp-2012-304874

Topics

Cite this paper

@article{Sekiguchi2013AmbiguousEO, title={Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome.}, author={Yukari Sekiguchi and Sonoko Misawa and Kazumoto Shibuya and Saiko Nasu and Satsuki Mitsuma and Yuta Iwai and Minako Beppu and Setsu Sawai and Shoichi Ito and Shigeki Hirano and Chiaki Nakaseko and Satoshi Kuwabara}, journal={Journal of neurology, neurosurgery, and psychiatry}, year={2013}, volume={84 12}, pages={1346-8} }